Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 467

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 467
---
| Total financial assets                   | ​ | $     | 37,903 | ​ | $                  | 37,903 | ​ | $                 | — | ​ | $            | — |

There were purchases, sales or maturities of Level 3 financial assets and unrealized gains or losses related to Level 3 available-for-sale marketable securities during each of the three months ended March 31, 2025 and 2024. There were transfers of financial assets into or out of Level 3 classification during the three months endedMarch 31, 2025 and 2024.

5.Restricted Cash

Cara historically had restricted cash balances that related to former lease agreements that terminated in prior periods. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Condensed Consolidated Statements of Cash Flows. For the three months ended March 31, 2024, $ of restricted cash became unrestricted in January 2024 and $ of restricted cash became unrestricted in October 2024 in relation to the termination of these former lease agreements. There was restricted cash as of March 31, 2025 or December 31, 2024.

| ​                                                                                                              | ​ 
 ​ | ​ |              ​ 
 March 31, 2025 | ​ | ​ |                 ​ 
 December 31, 2024 |
|:---------------------------------------------------------------------------------------------------------------|:--|:--|---------------:|:--|:--|------------------:|
| Cash and cash equivalents                                                                                      | ​ | $ |         34,217 | ​ | $ |            37,903 |
| Restricted cash, current assets                                                                                | ​ |   |              — | ​ |   |                 — |
| Restricted cash, long-term assets                                                                              | ​ |   |              — | ​ |   |                 — |
| Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows | ​ | $ |         34,217 | ​ | $ |            37,903 |

F- 114

TVARDI THERAPEUTICS, INC. (Formerly Cara Therapeutics, Inc.) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (amounts in thousands, except share and per share data) (unaudited)

6.Inventory, net

Inventory, net consists of the following:

| ​